Literature DB >> 26678088

Long-term Expectations of Vagus Nerve Stimulation: A Look at Battery Replacement and Revision Surgery.

Jonathan D Couch1, Arthur M Gilman, Werner K Doyle.   

Abstract

BACKGROUND: Vagus nerve stimulation (VNS) is an established surgical treatment for medically intractable epilepsy with more than 75 000 devices implanted worldwide. While there are many reports documenting efficacy, complications, and clinical use, there are very few reports concerning VNS battery replacement and revision surgeries.
OBJECTIVE: To review our experience with VNS battery replacement and revision surgery.
METHODS: We retrospectively reviewed 1144 consecutive VNS procedures performed by a single surgeon between 1998 and 2012. Six hundred forty-four of those procedures were the initial placement of the VNS device. These patients were then followed to determine when a battery change occurred and what type of revision or removal was necessary.
RESULTS: In the study, 46% of patients required at least 1 or more type of battery replacement or revision surgery. The most common types of surgery were for generator battery depletion (27%), poor efficacy (9%), and lead malfunction (8%). Only 2% of patients were noted to have an infection.
CONCLUSION: VNS battery replacement, revisions, and removals account for almost one-half of all VNS procedures. Our findings suggest important long-term expectations for VNS including expected complications, battery life, and other surgical issues. Review of the literature suggests that this is the first large review of VNS revisions by a single center. Our findings are important to better characterize long-term surgical expectations of VNS therapy. A significant portion of patients undergoing VNS therapy will eventually require revision.

Entities:  

Mesh:

Year:  2016        PMID: 26678088     DOI: 10.1227/NEU.0000000000000985

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  9 in total

1.  High lead impedances requiring revision during vagal nerve stimulator generator replacement.

Authors:  Pouya Entezami; John W German; Matthew A Adamo
Journal:  Acta Neurochir (Wien)       Date:  2020-09-24       Impact factor: 2.216

2.  Perioperative antibiotic use in vagus nerve stimulator implantation: a clinical series.

Authors:  Jeffrey S Raskin; Daniel Hansen; Arvind Mohan; I-Wen Pan; Daniel J Curry; Sandi Lam
Journal:  Childs Nerv Syst       Date:  2017-03-20       Impact factor: 1.475

3.  Reinstatement of contextual conditioned anxiety in virtual reality and the effects of transcutaneous vagus nerve stimulation in humans.

Authors:  Hannah Genheimer; Marta Andreatta; Esther Asan; Paul Pauli
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

Review 4.  A review of vagus nerve stimulation as a therapeutic intervention.

Authors:  Rhaya L Johnson; Christopher G Wilson
Journal:  J Inflamm Res       Date:  2018-05-16

5.  Vagal Nerve Stimulation in Epilepsy: Experiences of Participants with Cognitive Deficits.

Authors:  Eva Pipan; Alexandros Apostolou; Maria Bograkou; Petra Brooks; Patrick Vigren; Helena Gauffin
Journal:  Neuropsychiatr Dis Treat       Date:  2020-05-08       Impact factor: 2.570

6.  Surgical revision after Vagus Nerve Stimulation. A case series.

Authors:  Philipp Spindler; Peter Vajkoczy; Ulf Christoph Schneider
Journal:  Epilepsy Behav Rep       Date:  2021-03-26

Review 7.  Neurostimulation as a promising epilepsy therapy.

Authors:  Yicong Lin; Yuping Wang
Journal:  Epilepsia Open       Date:  2017-08-23

8.  Effect and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Recovery of Upper Limb Motor Function in Subacute Ischemic Stroke Patients: A Randomized Pilot Study.

Authors:  Dandong Wu; Jingxi Ma; Liping Zhang; Sanrong Wang; Botao Tan; Gongwei Jia
Journal:  Neural Plast       Date:  2020-08-01       Impact factor: 3.599

9.  Management and outcome of vagus nerve stimulator implantation: experience of an otolaryngeal/neuropediatric cooperation.

Authors:  S Grasl; S Janik; A Dressler; R Diehm; G Gröppel; K Eichinger; M C Grasl; W Gstoettner; M Feucht; E Vyskocil; W D Baumgartner
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-01       Impact factor: 2.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.